Skip to content

Advertisement

  • Research
  • Open Access

Efficacy of nitazoxanide to treat natural Giardia infections in dogs

  • 1,
  • 2,
  • 2,
  • 3 and
  • 1Email author
Parasites & Vectors201710:52

https://doi.org/10.1186/s13071-017-1998-7

  • Received: 7 June 2016
  • Accepted: 24 January 2017
  • Published:

Abstract

Background

Giardia parasites cause gastrointestinal disease in humans, dogs, and many other animals worldwide. The treatment of dogs for giardiasis requires further investigation to ascertain levels of drug efficacy and the possibility of adverse side effects. Nitazoxanide (NTZ) has shown good clinical anti-Giardia activity in humans, yet it has not been evaluated for the treatment of giardiasis in dogs.

Methods

Thirty-five dogs, naturally infected with Giardia were divided into five groups (n = 7): dogs in group NTZ1, NTZ2, and NTZ3 were treated with a single oral dose of 37.5 mg/kg, 75 mg/kg, and 150 mg/kg, respectively, of NTZ on days 0 and 14. The fourth group was treated with a commercially available regimen that includes a combination of pyrantel, praziquantel, and febantel (FEB) administered orally for three consecutive days. Additionally, an untreated control group was established. Giardia cysts from the stool of each dog were quantified on days -3, 0, 5, 7, 9, 11, 14, 18, 25, and 28. Biochemical parameters were evaluated in all dogs, before the first treatment and after concluding the experiment.

Results

Shedding of Giardia cysts was reduced in all treated groups when compared to untreated controls (P < 0.01). However, NTZ2, NTZ3, and FEB had a lower risk during the study. Furthermore, NTZ was also effective against another protozoan, Cryptosporidium spp. at doses of 75 mg/kg and 150 mg/kg, in contrast to the combination of febantel + pyrantel + praziquantel. Biochemical parameters of treated animals, namely, aspartate transaminase and alanine transaminase enzymes, remained within physiological ranges.

Conclusions

Based on these results, the implementation of NTZ as a treatment for giardiasis in dogs is proposed. The administration of a single dose is an important advantage of NTZ because it reduces workload, particularly in animals placed in shelters and kennels, where handling of large numbers of animals is required, and personnel is frequently scarce.

Keywords

  • Giardia
  • Nitazoxanide
  • Dogs
  • Parasite
  • Efficacy

Background

Canine giardiasis is caused by isolates of Giardia from four of the eight recognized genetic assemblages [1]. Of these, assemblage A and B have zoonotic potential [2]. Giardia has been described as the most commonly found parasite in dogs [3], though many infections are subclinical and remain undetected. Cysts and trophozoites of Giardia are shed in the faeces of all infected hosts [4], contaminating food, water, and the environment [5, 6]. Once a cyst has been ingested by a susceptible host, two trophozoites are released within the small intestine that will either remain free in the intestinal lumen or adhere to enterocytes causing damage to the microvilli and inducing the clinical signs of the infection. Trophozoites differentiate into cysts as they near the colon, completing their life-cycle in approximately 8 days [7]. Giardiasis is associated with a wide range of clinical signs, from diarrhea and malabsorption to a mild gastrointestinal discomfort [8]. However, it has been stated that giardiasis should be treated in all positive dogs so that they do not remain a source of infection for other animals and humans [2].

Although not approved by many regulatory agencies, such as Food and Drug Administration (FDA), metronidazole is one of the most commonly used drugs to treat giardiasis in dogs [9]. The use of tinidazole, a derivative of metronidazole, has also been reported [10], yet it is unavailable in many countries. Adverse drug effects are common with these agents and include nausea, vomiting, diarrhea, general discomfort, and loss of appetite [11]. Fenbendazole and febantel possess activity against Giardia [10]. Albendazole has also been used to control this parasite, but bone marrow suppression has been associated with the use of this benzimidazole derivative in dogs and cats [12, 13]. There are other drugs with giardicidal activity, such as furazolidone, which can cause hemolysis in individuals with a deficiency in the glucose 6-phosphate dehydrogenase enzyme. Quinacrine is another available giardicidal compound, though it is poorly tolerated because it causes nausea, vomiting, and cramps [14]. Paramomycin is another potential giardicidal compound, but there is limited information on its use [1518]. While metronidazole has been regarded as the drug of choice for treating giardiasis, resistance has been documented in human cases of Giardia infection, possibly due to mechanisms that allow the protozoan to tolerate the oxidative stress caused by this drug [9].

Nitazoxanide (NTZ) is a relatively new drug that was approved by FDA in 2014 for the treatment of giardiasis in humans. It is also effective against Trichomonas spp., Entamoeba histolytica, Clostridium difficile, Clostridium perfringens, Helicobacter pylori, and Campylobacter jejuni [19]. It has been shown that NTZ has a similar efficacy for eliminating Giardia when compared to metronidazole, but has fewer adverse effects [2023]. To the best of our knowledge, there are no formal studies on the effect of NTZ against clinical infections of Giardia in dogs. Therefore, the current trial was carried out to assess its efficacy against this protozoan, using febantel as FDA approved standard.

Methods

Nitazoxanide preparation

Nitazoxanide (assigned purity, 99.53%) was kindly supplied by Shin Yang–Hangzhou, Shinyang Samwoo Fine Chemical CO. (Ningbo, China). Differential scanning calorimetric (DSC), infrared absorption spectroscopy, and 1H and 13C nuclear magnetic resonance spectroscopy revealed a lack of impurities. A 30% suspension was made using sodium benzoate, sucrose, xanthan gum, microcrystalline cellulose and carboxymethylcellulose sodium, anhydrous citric acid, sodium citrate dihydrate, acacia gum, sugar syrup, FD&C Red #40 and Artificial Powdered Meat Flavor PC-0170 (PF Inc., Florida, USA).

Animals

The work was carried out adhering to the guidelines of the Institutional Committee for Use and Care of Experimental Animals of the institution, according to the Mexican Official Regulation NOM-062-ZOO-1999 [24]. Sixty-five dogs, selected from a shelter in Texcoco, State of Mexico, Mexico, were screened for the presence of Giardia by microscopic examination of faeces after zinc sulfate centrifugation before the commencement of the study. Initially, 40 animals were included as they tested positive to Giardia on three occasions before the trial. Dogs infected with pathogens other than gastrointestinal parasites, as well as those with other ailments were excluded from the study. Dogs shedding fewer than 10 Giardia cysts per examined slide were excluded from the trial. Thus, 14 male and 21 female dogs, 1.42 ± 0.5 years old on average and weighing 14.4 ± 2.5 kg (average) were included in this study. All dogs had lived in the shelter for more than 3 months and had not received any antiparasitic treatment in at least 3 months. Upon their arrival to the shelter, they were treated with a single dose of oxibendazole and niclosamide paste (Vitaminthe® Reforzado, Virbac, Mexico). Animals were allocated to individual rooms (1.5 × 3.0 m), separated from each other with wire mesh and with 70% humidity. They were fed commercial food without nutraceuticals (Ol’ Roy Adulto, México) ad libitum, had free access to water and soft bedding. The enclosures were cleaned daily and the dogs’ comfort was ensured.

Experimental design

A randomized non-inferiority study was conducted for the treatment of canine giardiasis, comparing the efficacy of three different doses of nitazoxanide administered every 14 days, to that of a FDA-approved reference antiparasitic product containing pyrantel embonate, febantel and praziquantel (Drontal Plus®, Bayer Animal Health, Mexico) administered for three consecutive days according to the manufacturer’s recommended dosage. The giardicidal efficacy of the investigational product was required to be equal to the reference product to achieve non-inferiority.

This trial was conducted according to the guidelines of the World Association for the Advancement of Veterinary Parasitology (WAAVP) for dose determination studies. This document states that one internationally accepted design includes a minimum of three groups receiving different dosages of the investigational drug together with an untreated control group [25]. Nitazoxanide has been experimentally administered to Giardia-infected dogs previously at an oral dose of 25 mg/kg twice a day, with no efficacy, as 37.5 to 50% of dogs that completed the experimental protocol, remained positive for Giardia [26]. Considering that 50 mg/kg/day was not effective against giardiasis in dogs, a dose of 75 mg/kg was selected, hoping to achieve a greater efficacy. Furthermore, previous experiments tested the anthelmintic efficacy of NTZ orally administered to dogs at a dose of 75–200 mg/kg, and a high efficacy against cestodes and nematodes was obtained [27].

All dogs were weighed on an electronic scale before treatment and blood samples were collected for hematological and biochemical analysis before drug dosing and 2 days after the last treatment. For allocation purposes, systematic random sampling was used. Animals were ranked from lowest to highest Giardia cyst count determined on day zero (0) before treatments and assigned to one of the five groups (n = 7).

Groups 1 (NTZ1), 2 (NTZ2), and 3 (NTZ3) were treated orally with the nitazoxanide paste preparation at a dose of 37.5 mg/kg, 75 mg/kg, or 150 mg/kg, respectively, on days 0 and 14 of the trial. The FEB group received the FDA-approved reference commercial antiparasitic product formulated as a tablet, which included a dose of 15 mg/kg of febantel, 5 mg/kg of praziquantel, and 14.4 mg/kg of pyrantel embonate (Drontal Plus®, Bayer Animal Health, Mexico) on days 0, 1, and 2 of the experiment, as recommended by the manufacturer. An untreated control group (CTRL) was also established, and received a placebo paste that contained the following excipients: sodium benzoate, sucrose, xanthan gum, microcrystalline cellulose and carboxymethylcellulose sodium, anhydrous citric acid, sodium citrate dihydrate, acacia gum, sugar syrup, FD&C Red #40 and artificial powdered meat flavor PC-0170. All dogs were observed for 6 h after treatment for vomiting or other adverse reactions.

In accordance with the guidelines of WAAVP, [10, 25, 28], three fecal samples were examined by microscopic examination after zinc sulfate centrifugation to determine the presence of Giardia cysts 3 days before administering the drugs, as well as the day that treatments were administered (Day 0) and on days 5, 7, 9, 11, 14, 18, 25 & 28 [29]. The number of Giardia cysts per slide was quantified by microscopy and cyst scores (0–4) were determined as follows: 0 = 0 cysts per slide; 1 = 1–100 cysts per slide; 2 = 100–300 cysts per slide; 3 = 300–500 cysts per slide; 4 = TNTC (too numerous to count) per 10× objective field [30, 31]. Additionally, the flotation technique was conducted to detect Cystoisospora oocysts and nematode eggs. The Graham and Kinyoun techniques were carried out to detect Dipylidium caninum egg packets or Cryptosporidium oocysts, respectively [32, 33]. To exclude a subjective decision, each sample was analyzed by three trained technicians in coprological diagnosis.

Fecal consistency was determined on days 0, 5, 7, 9, 11, 14, 18, 25 and 28, according to the following scale: 1 = liquid diarrhea; 2 = doughy and shapeless; 3 = soft and well-formed; 4 = hard, dry, firm, smooth and well-formed; 5 = very hard and dry [34, 35]. To avoid a biased interpretation, three technicians that did not participate in this study scored each individual sample to obtain fecal consistency data.

Biochemical parameters

Serum samples were processed to determine concentrations of aminotransferase alanine (ALT) and aspartate aminotransferase (AST), measured using a diagnostic kit (Spinreact, S.A. de C.V., Mexico) in a Cobas Mira analyzer (Roche, S.A. de C.V., Mexico), according to the manufacturer’s instructions.

Statistical analysis

Results were adjusted with generalized linear models, and with maximum likelihood estimation methods [36]. Odds ratios were also estimated for the analysis of cyst and faecal categories for each treatment against the control group. An ordinal logit regression model was constructed to allow a better understanding of the study variables (cyst scores and faecal consistency).

Results

Odds ratios (OR) calculated vs the control group are shown in Table 1. NTZ1, NTZ2, NTZ3 and FEB groups displayed diminished risk of shedding Giardia cysts as compared to untreated controls; yet NTZ2, NTZ3, and FEB were less likely to excrete Giardia cysts during the study (OR 0.559, 95% CI: 0.00–0.78, P = 0.001; OR 0.023, 95% CI: 0.015–0.036, P = 0.0001; OR 0.024, 95% CI: 0.015–0.038, P = 0.0001; OR 0.037, 95% CI: 0.024–0.038, P = 0.0001; respectively).
Table 1

Odds ratios (OR) and confidence intervals (CI) of cyst scores for groups treated with, or without, nitazoxanide or with pyrantel + praziquantel + febantel

Group

OR (vs CTRL)

95% CI

Times less than control (1/OR)

P

NTZ1

0.559

0.00–0.78

1.8

0.001

NTZ2

0.023

0.015–0.036

43.5

0.0001

NTZ3

0.024

0.015–0.038

41.6

0.0001

FEB

0.037

0.024–0.038

27.0

0.0001

Abbreviations: NTZ1 group treated with 37.5 mg/kg nitazoxanide, NTZ2 group treated with 75 mg/kg nitazoxanide, NTZ3 group treated with 150 mg/kg nitazoxanide, FEB group treated with pyrantel + praziquantel + febantel, CTRL untreated group

No cysts were detected in the feces of groups NTZ2 and NTZ3 until day 11. On day 14, cysts were found in stool samples from one dog of each of these two groups. After the administration of NTZ to groups NTZ2 and NTZ3 on day 14, no cysts were observed until the end of the experiment. On the other hand, in the FEB group, one dog shed Giardia cysts on days 9, 11, and 14 and two dogs excreted no cysts on days 18, 25, and 28. Nevertheless, no significant difference was obtained between NTZ2, NTZ3 and FEB groups (P > 0.05). It was also found that the administration of NTZ or febantel did not result in different faecal consistencies in comparison to untreated controls.

Before the initiation of this trial, stool samples from all dogs were screened to identify infections with other parasites. Only Giardia-infected dogs were included in the study. However, stool samples from these dogs were positive for at least one of the following parasites: Cystoisospora spp., Cryptosporidium spp., Toxocara canis, Ancylostoma caninum, Trichuris vulpis or Dipylidium caninum. After an appropriate anthelmintic treatment, no cestodes or nematodes were detected in stool samples, while Cystoisospora oocysts were found in all groups, as no anticoccidial drug was administered to the experimental animals. As for the activity of NTZ against other parasites, dogs treated with 75 mg/kg or 150 mg/kg did not shed Cryptosporidium oocysts; whereas animals in NTZ1 or FEB groups remained infected with this protozoan group (Table 2).
Table 2

Coccidia and helminths of dogs detected in feces before and after treatment with nitazoxanide (NTZ) or a combination of pyrantel + praziquantel + febantel (FEB)

Group

Dog

Age

(years)

Parasite

Day -3

Day 0

Day 14

Day 28

NTZ1

1

2

Cystoisospora sp.

+

+

+

+

  

Toxocara canis

+

2

1

Ancylostoma caninum

+

  

Toxocara canis

+

3

1

Cryptosporidium

+

+

+

+

  

Ancylostoma caninum

+

4

2

Dipylidium caninum

+

  

Toxocara canis

+

  

Ancylostoma caninum

+

5

2

Cystoisospora

+

+

+

+

  

Dipylidium caninum

+

  

Trichuris vulpis

+

6

2

Ancylostoma caninum

+

  

Trichuris vulpis

+

7

1

Cystoisospora

+

+

+

+

  

Cryptosporidium

+

+

+

+

  

Toxocara canis

+

  

Ancylostoma caninum

+

NTZ2

8

1

Cryptosporidium

+

+

-

-

  

Ancylostoma caninum

+

  

Trichuris vulpis

+

9

2

Cystoisospora

+

+

+

+

  

Toxocara canis

+

  

Dipylidium caninum

+

10

1

Ancylostoma caninum

+

  

Trichuris vulpis

+

11

1

Cystoisospora

+

+

+

+

  

Ancylostoma caninum

+

  

Toxocara canis

+

12

2

Cystoisospora

+

+

+

+

  

Trichuris vulpis

+

-

  

Dipylidium caninum

+

13

1

Cryptosporidium

+

+

-

-

  

Cystoisospora

+

+

+

  

Ancylostoma caninum

+

  

Dipylidium caninum

+

14

1

Ancylostoma caninum

+

  

Toxocara canis

+

  

Trichuris vulpis

+

NTZ3

15

1

Cystoisospora

+

+

+

+

16

1

Cryptosporidium

+

+

-

-

  

Cystoisospora

+

+

+

+

  

Toxocara canis

+

17

1

Ancylostoma caninum

+

  

Toxocara canis

+

  

Trichuris vulpis

+

  

Dipylidium caninum

+

18

1

Ancylostoma caninum

+

19

2

Cryptosporidium

+

+

-

-

  

Cystoisospora

+

+

+

+

  

Trichuris vulpis

+

20

2

Ancylostoma caninum

+

  

Trichuris vulpis

+

21

1

Cryptosporidium

+

+

-

-

  

Trichuris vulpis

+

  

Dipylidium caninum

+

FEB

22

2

Cryptosporidium

+

+

+

+

  

Dipylidium caninum

+

23

1

Cystoisospora

+

+

+

+

  

Toxocara canis

+

24

1

Cystoisospora

+

+

+

+

  

Ancylostoma caninum

+

  

Trichuris vulpis

+

25

1

Cryptosporidium

+

+

+

+

  

Ancylostoma caninum

+

26

1

Cryptosporidium

+

+

+

+

  

Ancylostoma caninum

+

  

Trichuris vulpis

+

27

1

Cystoisospora

+

+

+

+

  

Toxocara canis

+

  

Ancylostoma caninum

+

28

1

Toxocara canis

+

CTRL

29

2

Dipylidium caninum

+

  

Toxocara canis

+

  

Ancylostoma caninum

+

30

2

Cryptosporidium

+

+

+

+

  

Cystoisospora

+

+

+

+

  

Dipylidium caninum

+

  

Trichuris vulpis

+

31

1

Toxocara canis

+

  

Ancylostoma caninum

+

32

1

Cystoisospora

+

+

+

+

  

Toxocara canis

+

  

Ancylostoma caninum

+

33

2

Cryptosporidium

+

+

+

+

  

Toxocara canis

+

34

2

Toxocara canis

+

35

1

Cystoisospora

+

+

+

+

  

Dipylidium caninum

+

  

Toxocara canis

+

Abbreviations: NTZ1 group treated with 37.5 mg/kg nitazoxanide, NTZ2 group treated with 75 mg/kg nitazoxanide, NTZ3 group treated with 150 mg/kg nitazoxanide, FEB group treated with pyrantel + praziquantel + febantel, CTRL untreated group

The therapeutic protocols used in this study did not affect AST and ALT levels in any dog from NTZ1, NTZ2, NTZ3, and FEB groups. Regarding the overall health of experimental animals, vomiting occurred in a single dog treated with 150 mg/kg nitazoxanide during the treatment administration on day 14.

Discussion

Options for the treatment of giardiasis in dogs are limited, and the few available drugs are often accompanied by adverse reactions [12]. For example, it has been documented that metronidazole administered to dogs at a rate of 22 mg/kg, twice daily for 5 days, induces vomiting and neurological dysfunctions. Additionally, this drug has mutagenic and carcinogenic potential [1, 37]. Albendazole has been linked to vomiting, bloody diarrhea, abortion, and teratogenicity [38]. Thus, the only available option at present for the treatment of canine giardiasis is febantel; a drug usually combined with praziquantel and pyrantel, administered for three consecutive days, as in the FEB group in this trial.

This study indicates that the anti-Giardia activity of 75 mg/kg or 150 mg/kg NTZ or the combination of antiparasitic drugs containing febantel, was similar. This finding is consistent with previous reports that document the giardicidal efficacy of febantel [28, 38, 39]. Nevertheless, results obtained in the present trial demonstrate that cysts were recovered from the FEB-treated dogs six days after the last treatment. This observation agrees with previous studies that showed an increase in the number of dogs shedding cysts and the number of cysts shed by dogs, beginning six days after treatment with this same combination [38]. Other reports state that there appears to be no significant improvement when febantel is given to Giardia-infected dogs for three or five consecutive days [28]. On the other hand, the administration of 75 mg/kg or 150 mg/kg NTZ in the present study, halted the shedding of Giardia cysts by dogs for 13 days. Hence, it is reasonable to suggest that a single dose of NTZ at 75 mg/kg or 150 mg/kg results in reduced shedding of cysts when compared to febantel. In contrast, the data generated in the present study shows a lack of a statistically significant difference between cyst output in dogs that received a single dose of NTZ at 37.5 mg/kg when compared to untreated controls.

To the best of our knowledge, this is the first study to confirm the high efficacy of NTZ for reducing Giardia cyst shedding in dogs. A previous study documented shedding of Giardia cysts in infected dogs five days after the administration of NTZ at a dosage of 25 mg/kg two times a day. [26]. In the present study, the cyst shedding pattern of the NTZ1 (37.5 mg/kg) group was similar to that of the untreated controls during the experiment. In contrast, dogs that received a single dose of 75 mg/kg or 150 mg/kg, showed a reduction in cyst shedding. In this case, the presence of parasite cysts after treating dogs could be attributable to reinfection. Giardia has a short prepatent period of 5 days and cysts are resistant to disinfectants and environmental conditions. These factors, together with stress and the presence of cysts in the animal’s fur, may explain reinfection [38].

Regarding the effect of the administration of NTZ or febantel on faecal consistency, the results of this study do not concur with previous findings, which demonstrated that faeces could be shapeless to diarrheic in untreated dogs as compared to febantel treated dogs [28]. However, all Giardia-infected dogs were also infected with at least one helminth or protozoan, such as Cystoisospora spp. which did not respond to NTZ treatment. Infections caused by coccidia are associated with abnormal faecal consistency and deterioration of faecal scores [40, 41]. The presence of coccidia in the stool of dogs could account for the abnormal consistency of stool specimens despite anti-Giardia treatment, supporting the hypothesis of the potential significance of cystoisosporosis as an associated cause of diarrhea in dogs. One major limitation of this study was the lack of an uninfected control group, which could have confirmed the absence of a clear association between fecal consistency and Giardia infection [4245].

In addition to the observed giardicidal activity of nitazoxanide administered at 75 mg/kg or 150 mg/kg, anti-Cryptosporidium activity was observed. This finding coincides with data reported in previous experiments, which demonstrated that nitazoxanide dosages ranging from 50 to 250 mg/kg reduce Cryptosporidium oocyst excretion in laboratory animals and goats [46]. It should be noted that nitazoxanide is the only drug approved by the FDA in humans, as a treatment option for cryptosporidiosis [47].

Dogs kept in kennels or shelters are more susceptible to suffer from anorexia, anemia, and diarrhea caused by gastrointestinal helminths and protozoans, given that these places include young, old, and immunocompromised animals. Indeed, co-infection with several intestinal parasites is frequently reported in kennels and shelters, involving parasites such as Giardia, Toxocara canis, Cryptosporidium spp., Ancylostoma caninum, Capillaria aerophila [48], Toxascaris leonina, Uncinaria stenocephala, Trichuris vulpis, Sarcocystis spp., capillariid eggs [49, 50], and Cystoisospora spp. [51]. Therefore, broad-spectrum drug formulations are most suitable in these cases [41]. Indeed, NTZ administered at a dose of 75 mg/kg could represent a suitable drug for use under these circumstances.

In this work, virtually no adverse reactions were observed, much in agreement with other studies [23]. Vomiting occurred in one dog after the administration of 150 mg/kg of NTZ. This result agrees with the study by Basu et al. [52], who reported nausea in 9% of patients treated with this compound. This may suggest that the lower dose of 75 mg/kg is marginally safer, though further research is required. In contrast, it has been proposed that fenbendazole, the active form of febantel, may promote liver tumors because it induces upregulation of cytochrome P-450 isozymes (CYP) 2B1/2, which are involved in hepatocarcinogenesis [53]. Finally, it is important to reiterate that the therapeutic use of antiparasitic drugs in kennels and shelters, should not be the only measure employed to control these infections. Dog bathing and the frequent cleaning and disinfection of their environment, reduces the risk of infection and re-infection [28]. In fact, studies have demonstrated that dogs re-shed cysts following a brief period after antiparasitic treatment when no disinfection or cleaning of their enclosures is performed. Shampooing of dogs is recommended because fecal material on the fur increases the chance of reinfection [5457].

The results of the current study suggest that administration of 75 mg/kg of NTZ every 14 days is effective for the treatment of giardiasis and cryptosporidiosis in dogs, though this requires further evaluation.

Conclusions

This study demonstrates that the administration of 75 mg/kg of NTZ every 14 days to dogs infected with Giardia reduces cyst excretion. Data from this study will help in the development of Giardia control programmes, particularly in shelter animals.

Abbreviations

CTRL: 

Non-treated group

FEB: 

Group treated with pirantel + praziquantel + febantel

TNTC: 

Too numerous to count.

NTZ: 

Nitazoxanide

NTZ1: 

Group treated with 37.5 mg/kg nitazoxanide

NTZ2: 

Group treated with 75 mg/kg nitazoxanide

NTZ3: 

Group treated with 150 mg/kg nitazoxanide

Declarations

Acknowledgements

The authors are grateful to Juan Antonio Figueroa-Castillo and Aldo Bruno Alberti-Navarro for technical assistance.

Funding

Funding from DGAPA PAPIME PE202416 is gratefully acknowledged.

Availability of data and materials

The datasets supporting the conclusions of this article are available in the Zenodo repository [DOI 10.5281/zenodo.55041 and in https://zenodo.org/record/55041].

Authors’ contributions

Contributed to the study design, carried out the experiments, performed laboratory analysis, collaborated with results interpretation, data analysis, manuscript revision and discussion: MMS, YAC, LGO, GTP and HSL. Performed statistical data analysis and suggested the experimental design: GTP. Wrote the paper: MMS and YAC with input from HSL, GTP and LGO. Grant funding: YAC. Supervision of experiments and laboratory procedures: YAC, LGO and HSL. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval

The work was carried out adhering to the guidelines of the Institutional Committee for Use and Care of Experimental Animals of the institution, according to the Mexican Official Regulation NOM-062-ZOO-1999.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Departamento de Parasitología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Av. Universidad 3000, Delegación Coyoacán, Ciudad de México, C.P., 04510, Mexico
(2)
Departamento de Fisiología y Farmacología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Av. Universidad 3000, Delegación Coyoacán, Ciudad de México, C.P., 04510, Mexico
(3)
Departamento de Genética y Bioestadística, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Av. Universidad 3000, Delegación Coyoacán, Ciudad de México, C.P., 04510, Mexico

References

  1. Ballweber LR, Xiao L, Bowman DD, Kahn G, Cama VA. Giardiasis in dogs and cats: update on epidemiology and public health significance. Trends Parasitol. 2010;26:180–9.View ArticlePubMedGoogle Scholar
  2. McDowall RM, Peregrine AS, Leonard EK, Lacombe C, Lake M, Rebelo AR, et al. Evaluation of the zoonotic potential of Giardia duodenalis in fecal samples from dogs and cats in Ontario. Can Vet J. 2011;52:1329–33.PubMedPubMed CentralGoogle Scholar
  3. Bugg RJ, Robertson ID, Elliot AD, Thompson RC. Gastrointestinal parasites of urban dogs in Perth, western Australia. Vet J. 1999;157:295–301.View ArticlePubMedGoogle Scholar
  4. Uehlinger FD, Greenwood SJ, McClure JT, Conboy G, O’Handley R, Barkema HW. Zoonotic potential of Giardia duodenalis and Cryptosporidium spp. and prevalence of intestinal parasites in young dogs from different populations on Prince Edward Island, Canada. Vet Parasitol. 2013;196:509–14.View ArticlePubMedGoogle Scholar
  5. Mohamed AS, Glickman LT, Camp JW, Lund E, Moore GE. Prevalence and risk factors for Giardia spp. infection in a large national sample of pet dogs visiting veterinary hospitals in the United States (2003–2009). Vet Parasitol. 2013;195:35–41.View ArticlePubMedGoogle Scholar
  6. Mohamed AS, Levine M, Camp JW, Lund E, Yoder JS, Glickman LT, et al. Temporal patterns of human and canine Giardia infection in the United States: 2003-2009. Prev Vet Med. 2014;113:249–56.View ArticlePubMedGoogle Scholar
  7. Ortuño A, Scorza V, Castellà J, Lappin M. Prevalence of intestinal parasites in shelter and hunting dogs in Catalonia, Northeastern Spain. Vet J. 2014;199:465–7.View ArticlePubMedGoogle Scholar
  8. Sotiriadou I, Pantchev N, Gassmann D, Karanis P. Molecular identification of Giardia and Cryptosporidium from dogs and cats. Parasite. 2013;20:8.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Ansell BR, McConville MJ, Ma’ayeh SY, Dagley MJ, Gasser RB, Svärd SG, et al. Drug resistance in Giardia duodenalis. Biotechnol Adv. 2015;33:888–901.View ArticlePubMedGoogle Scholar
  10. Fiechter R, Deplazes P, Schnyder M. Control of Giardia infections with ronidazole and intensive hygiene management in a dog kennel. Vet Parasitol. 2012;187:93–8.View ArticlePubMedGoogle Scholar
  11. Shukla G, Kaur H, Sharma L. Comparative therapeutic effect of probiotic Lactobacillus casei alone and in conjunction with antiprotozoal drugs in murine giardiasis. Parasitol Res. 2013;112:2143–9.View ArticlePubMedGoogle Scholar
  12. Tangtrongsup S, Scorza V. Update on the diagnosis and management of Giardia spp infections in dogs and cats. Top Companion Anim Med. 2010;25:155–62.View ArticlePubMedGoogle Scholar
  13. Stokol T, Randolph JF, Nachbar S, Rodi C, Barr SC. Development of bone marrow toxicosis after albendazole administration in a dog and cat. J Am Vet Med Assoc. 1997;210:1753–6.PubMedGoogle Scholar
  14. Gardner TB, Hill DR. Treatment of giardiasis. Clin Microbiol Rev. 2001;14:114–28.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Gekonge B, Bardin MC, Montaner LJ. Nitazoxanide inhibits HIV viral replication in monocyte-derived macrophages. AIDS Res Hum Retroviruses. 2015;31:237–41.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Navarrete-Vázquez G, Chávez-Silva F, Colín-Lozano B, Estrada-Soto S, Hidalgo-Figueroa S, Guerrero-Álvarez J, et al. Synthesis of nitro(benzo)thiazole acetamides and in vitro antiprotozoal effect against amitochondriate parasites Giardia intestinalis and Trichomonas vaginalis. Bioorg Med Chem. 2015;23:2204–10.View ArticlePubMedGoogle Scholar
  17. Rossignol JF, Lopez-Chegne N, Julcamoro LM, Carrion ME, Bardin MC. Nitazoxanide for the empiric treatment of pediatric infectious diarrhea. Trans R Soc Trop Med Hyg. 2012;106:167–73.View ArticlePubMedGoogle Scholar
  18. Soria-Arteche O, Hernández-Campos A, Yépez-Mulia L, Trejo-Soto PJ, Hernández-Luis F, Gres-Molina J, et al. Synthesis and antiprotozoal activity of nitazoxanide-N-methylbenzimidazole hybrids. Bioorg Med Chem Lett. 2013;23:6838–41.View ArticlePubMedGoogle Scholar
  19. Di Santo N, Ehrisman J. A functional perspective of nitazoxanide as a potential anticancer drug. Mutat Res. 2014;768:16–21.View ArticlePubMedGoogle Scholar
  20. Martínez-Gordillo MN, González-Maciel A, Reynoso-Robles R, Montijo-Barrios E, Ponce-Macotela M. Intraepithelial Giardia intestinalis: a case report and literature review. Medicine (Baltimore). 2014;93:e277.View ArticleGoogle Scholar
  21. Monárrez-Espino J, Pérez-Espejo CR, Vázquez-Mendoza G, Balleza-Carreón A, Caballero-Hoyos R. Intervention to prevent intestinal parasitic reinfections among Tarahumara indigenous schoolchildren in northern Mexico. Rev Panam Salud Publica. 2011;30:196–203.View ArticlePubMedGoogle Scholar
  22. Müller J, Schildknecht P, Müller N. Metabolism of nitro drugs metronidazole and nitazoxanide in Giardia lamblia: characterization of a novel nitroreductase (GlNR2). J Antimicrob Chemother. 2013;68:1781–9.View ArticlePubMedGoogle Scholar
  23. Senkowski W, Zhang X, Olofsson MH, Isacson R, Höglund U, Gustafsson M, et al. Three-dimensional cell culture-based screening identifies the anthelmintic drug nitazoxanide as a candidate for treatment of colorectal cancer. Mol Cancer Ther. 2015;14:1504–16.View ArticlePubMedGoogle Scholar
  24. SAGARPA. Norma oficial Mexicana NOM-062-ZOO-1999. Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio. México: Diario Oficial de la Federación; 1999. http://www.ibt.unam.mx/computo/pdfs/bioterio.NOM-062.pdf.Google Scholar
  25. Geurden T, Olson ME, O’Handley RM, Schetters T, Bowman D, Vercruysse J. World Association for the Advancement of Veterinary Parasitology (WAAVP): Guideline for the evaluation of drug efficacy against non-coccidial gastrointestinal protozoa in livestock and companion animals. Vet Parasitol. 2014;204:81–6.View ArticlePubMedGoogle Scholar
  26. Lappin MR, Clark M, A.V. S: Treatment of healthy Giardia spp. positive dogs with fenbendazole or nitazoxanide. In: Proceedings of the ACVIM Forum 2008;778.Google Scholar
  27. Murphy JR, Friedmann JC. Pre-clinical toxicology of nitazoxanide - a new antiparasitic compound. J Appl Toxicol. 1985;5:49–52.View ArticlePubMedGoogle Scholar
  28. Montoya A, Dado D, Mateo M, Espinosa C, Miró G. Efficacy of drontal flavour plus (50 mg praziquantel, 144 mg pyrantel embonate, 150 mg febantel per tablet) against Giardia sp. in naturally infected dogs. Parasitol Res. 2008;103:1141–4.View ArticlePubMedGoogle Scholar
  29. Faust EC, Jung RC. Protozoan and metazoan parasitoses of the intestinal tract. Pediatr Clin North Am. 1956;3:169–90.View ArticleGoogle Scholar
  30. Chon SK, Kim NS. Evaluation of silymarin in the treatment on asymptomatic Giardia infections in dogs. Parasitol Res. 2005;97:445–51.View ArticlePubMedGoogle Scholar
  31. Scorza AV, Radecki SV, Lappin MR. Efficacy of a combination of febantel, pyrantel, and praziquantel for the treatment of kittens experimentally infected with Giardia species. J Feline Med Surg. 2006;8:7–13.View ArticlePubMedGoogle Scholar
  32. Thienpont D, Rochett F, Vanparijs OF. Diagnosing helminthiasis by coprological examination. 2nd. ed. Beerse: Janssen Research Foundation; 1979.Google Scholar
  33. Vanparijs O, Hermans L, van der Flaes L. Helminth and protozoan parasites in dogs and cats in Belgium. Vet Parasitol. 1991;38:67–73.View ArticlePubMedGoogle Scholar
  34. Zentek J, Marquart B, Pietrzak T. Intestinal effects of mannanoligosaccharides, transgalactooligosaccharides, lactose and lactulose in dogs. J Nutr. 2002;132:1682S–4S.PubMedGoogle Scholar
  35. Zentek J, Hall EJ, German A, Haverson K, Bailey M, Rolfe V, et al. Morphology and immunopathology of the small and large intestine in dogs with nonspecific dietary sensitivity. J Nutr. 2002;132:1652S–4S.PubMedGoogle Scholar
  36. McCullag P, Nelder JA. Generalized linear models. 2nd. ed. New York: Chapman and Hall/CRC; 1989.Google Scholar
  37. Giangaspero A, Traldi G, Paoletti B, Traversa D, Bianciardi P. Efficacy of pyrantel embonate, febantel and praziquantel against Giardia species in naturally infected adult dogs. Vet Rec. 2002;150:184–6.View ArticlePubMedGoogle Scholar
  38. Bowman DD, Liotta JL, Ulrich M, Charles SD, Heine J, Schaper R. Treatment of naturally occurring, asymptomatic Giardia sp. in dogs with Drontal Plus flavour tablets. Parasitol Res. 2009;105:S125–34.View ArticlePubMedGoogle Scholar
  39. Rinaldi L, Pennacchio S, Musella V, Maurelli MP, La Torre F, Cringoli G. Helminth control in kennels: is the combination of milbemycin oxime and praziquantel a right choice? Parasit Vectors. 2015;8:30.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Lindsay DS, Houk AE, Mitchell SM, Dubey JP. Developmental biology of Cystoisospora (Apicomplexa: Sarcocystidae) monozoic tissue cysts. J Parasitol. 2014;100:392–8.View ArticlePubMedGoogle Scholar
  41. Houk AE, O’Connor T, Pena HF, Gennari SM, Zajac AM, Lindsay DS. Experimentally induced clinical Cystoisospora canis coccidiosis in dogs with prior natural patent Cystoisospora ohioensis-like or C. canis infections. J Parasitol. 2013;99:892–5.View ArticlePubMedGoogle Scholar
  42. Winsland JK, Nimmo S, Butcher PD, Farthing MJ. Prevalence of Giardia in dogs and cats in the United Kingdom: survey of an Essex veterinary clinic. Trans R Soc Trop Med Hyg. 1989;83:791–2.View ArticlePubMedGoogle Scholar
  43. Itoh N, Kanai K, Kimura Y, Chikazawa S, Hori Y, Hoshi F. Prevalence of intestinal parasites in breeding kennel dogs in Japan. Parasitol Res. 2015;114:1221–4.View ArticlePubMedGoogle Scholar
  44. Papini R, Gorini G, Spaziani A, Cardini G. Survey on giardiosis in shelter dog populations. Vet Parasitol. 2005;128:333–9.View ArticlePubMedGoogle Scholar
  45. Upjohn M, Cobb C, Monger J, Geurden T, Claerebout E, Fox M. Prevalence, molecular typing and risk factor analysis for Giardia duodenalis infections in dogs in a central London rescue shelter. Vet Parasitol. 2010;172:341–6.View ArticlePubMedGoogle Scholar
  46. Viel H, Rocques H, Martin J, Chartier C. Efficacy of nitazoxanide against experimental cryptosporidiosis in goat neonates. Parasitol Res. 2007;102:163–6.View ArticlePubMedGoogle Scholar
  47. Miyamoto Y, Eckmann L. Drug development against the major siarrhea-causing parasites of the small intestine, Cryptosporidium and Giardia. Front Microbiol. 2015;6:1208.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Paoletti B, Traversa D, Iorio R, De Berardinis A, Bartolini R, Salini R, et al. Zoonotic parasites in feces and fur of stray and private dogs from Italy. Parasitol Res. 2015;114:2135–41.View ArticlePubMedGoogle Scholar
  49. Villeneuve A, Polley L, Jenkins E, Schurer J, Gilleard J, Kutz S, et al. Parasite prevalence in fecal samples from shelter dogs and cats across the Canadian provinces. Parasit Vectors. 2015;8:281.View ArticlePubMedPubMed CentralGoogle Scholar
  50. Becker AC, Rohen M, Epe C, Schnieder T. Prevalence of endoparasites in stray and fostered dogs and cats in northern Germany. Parasitol Res. 2012;111:849–57.View ArticlePubMedGoogle Scholar
  51. Simonato G, Frangipane Di Regalbono A, Cassini R, Traversa D, Beraldo P, Tessarin C, et al. Copromicroscopic and molecular investigations on intestinal parasites in kenneled dogs. Parasitol Res. 2015;114:1963–70.View ArticlePubMedGoogle Scholar
  52. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011;106:1970–5.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Shoda T, Onodera H, Takeda M, Uneyama C, Imazawa T, Takegawa K, et al. Liver tumor promoting effects of fenbendazole in rats. Toxicol Pathol. 1999;27:553–62.View ArticlePubMedGoogle Scholar
  54. Geurden T, Vercruysse J, Claerebout E. Field testing of a fenbendazole treatment combined with hygienic and management measures against a natural Giardia infection in calves. Vet Parasitol. 2006;142:367–71.View ArticlePubMedGoogle Scholar
  55. Villeneuve V, Beugnet F, Bourdoiseau G. Efficacy of oxfendazole for the treatment of giardiosis in dogs. Experiments in dog breeding kennels. Parasite. 2000;7:221–6.View ArticlePubMedGoogle Scholar
  56. Payne PA, Ridley RK, Dryden MW, Bathgate C, Milliken GA, Stewart PW. Efficacy of a combination febantel-praziquantel-pyrantel product, with or without vaccination with a commercial Giardia vaccine, for treatment of dogs with naturally occurring giardiasis. J Am Vet Med Assoc. 2002;220:330–3.View ArticlePubMedGoogle Scholar
  57. Zajac AM, LaBranche TP, Donoghue AR, Chu TC. Efficacy of fenbendazole in the treatment of experimental Giardia infection in dogs. Am J Vet Res. 1998;59:61–3.PubMedGoogle Scholar

Copyright

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement